Literature DB >> 15528919

A note on gelastic epilepsy.

J M S Pearce1.   

Abstract

Laughter epilepsy or gelastic seizures have been described in various epilepsies arising from the temporal or frontal lobes, but most commonly from hypothalamic hamartomata. Gelastic seizures also arise from temporal and frontal lobe tumours and atrophic lesions. The essential clinical features are: stereotyped recurrence; absence of external precipitants; concomitance of other manifestations generally accepted as epileptic; presence of interictal or interictal EEG epileptiform discharges, and absence of conditions in which pathological laughter might occur. The history and clinical significance are discussed. 2004 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2004        PMID: 15528919     DOI: 10.1159/000081858

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  5 in total

Review 1.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  Cingulate gyrus epilepsy: clinical and behavioral aspects, with surgical outcomes.

Authors:  Rafeed Alkawadri; Bruce E Mickey; Christopher J Madden; Paul C Van Ness
Journal:  Arch Neurol       Date:  2011-03

3.  Cryptogenic gelastic epilepsy: a pediatric case vignette.

Authors:  Devendra Mishra; Monica Juneja; Taruna Chutani; Debashish Chowdhury
Journal:  J Clin Diagn Res       Date:  2014-03-15

4.  Transcallosal resection of hypothalamic hamartoma for gelastic epilepsy.

Authors:  M Andrew; J R Parr; R Stacey; J V Rosenfeld; Y Hart; P Pretorius; S Nijhawan; Z Zaiwalla; M A McShane
Journal:  Childs Nerv Syst       Date:  2007-09-09       Impact factor: 1.475

5.  Abnormal laughter-like vocalisations replacing speech in primary progressive aphasia.

Authors:  Jonathan D Rohrer; Jason D Warren; Martin N Rossor
Journal:  J Neurol Sci       Date:  2009-05-12       Impact factor: 3.181

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.